The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the Clinical Practice Guidelines. Introductory webinars accompany each CPG and describe recommended uses of immunotherapies for a specific disease state and how to appropriately manage common and uncomplicated toxicities.
New in 2021 are advanced webinars for selected CPGs. Practical Management Pearls webinars will cover optimal sequencing of immunotherapies in relapsed or refractory disease and integration of immunotherapies into treatment plans for early-stage cancers, as well as other advanced topics. Case Studies webinars will then discuss immunotherapy treatment regimens for challenging patient populations, in addition to how to identify and manage uncommon and/or atypically responsive disease.
Participate in a live webinar or view on-demand webinar content. To register for one or multiple upcoming webinars in a series, click on a “REGISTER NOW” button that may appear below. To view an on-demand webinar, click on any “View On-demand” link. A free SITC Connect account is required for both live and on-demand webinars (you will be prompted to create a SITC Connect account if you don’t already have one).
*The indicated introductory webinars are jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer. CE credits are available to live webinar attendees. These webinars are also supported, in part, by independent medical education grant funding from Amgen, AstraZeneca Pharmaceuticals LP, Celgene Corporation and Merck & Co., Inc. (unless noted otherwise).
The Practical Management Pearls and Case Studies Webinars are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/15/2021). CE credits are not available for these webinars.
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.